Kiniksa Pharmaceuticals (KNSA)
(Real Time Quote from BATS)
$26.02 USD
-0.23 (-0.88%)
Updated Sep 20, 2024 02:42 PM ET
2-Buy of 5 2
D Value D Growth F Momentum F VGM
Balance Sheet
Fiscal Year End for Kiniksa Pharmaceuticals, Ltd falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 206 | 191 | 182 | 324 | 233 |
Receivables | 21 | 13 | 4 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 31 | 22 | 4 | 0 | 0 |
Other Current Assets | 18 | 18 | 7 | 10 | 8 |
Total Current Assets | 276 | 243 | 196 | 333 | 242 |
Net Property & Equipment | 1 | 2 | 3 | 4 | 6 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 219 | 186 | 0 | 0 | 4 |
Intangibles | 17 | 18 | 19 | 0 | 0 |
Deposits & Other Assets | 1 | 6 | 9 | 6 | 0 |
Total Assets | 526 | 460 | 233 | 349 | 255 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 8 | 8 | 2 | 1 | 6 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 45 | 30 | 38 | 29 | 20 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 9 | 6 | 2 | 0 | 0 |
Total Current Liabilities | 64 | 47 | 45 | 32 | 28 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 12 | 12 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 2 | 2 | 0 | 1 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 87 | 64 | 48 | 38 | 29 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 917 | 888 | 860 | 829 | 581 |
Retained Earnings | -478 | -492 | -675 | -517 | -356 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 439 | 396 | 185 | 312 | 225 |
Total Liabilities & Shareholder's Equity | 526 | 460 | 233 | 349 | 255 |
Total Common Equity | 439 | 396 | 185 | 312 | 225 |
Shares Outstanding | 70.40 | 69.70 | 69.90 | 68.20 | 54.90 |
Book Value Per Share | 6.23 | 5.68 | 2.65 | 4.57 | 4.11 |
Fiscal Year End for Kiniksa Pharmaceuticals, Ltd falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 219 | 214 | 206 | 201 | 185 |
Receivables | 20 | 16 | 21 | 3 | 25 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 35 | 27 | 31 | 26 | 24 |
Other Current Assets | 27 | 14 | 18 | 26 | 12 |
Total Current Assets | 301 | 271 | 276 | 256 | 246 |
Net Property & Equipment | 1 | 1 | 1 | 1 | 1 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 204 | 215 | 219 | 194 | 204 |
Intangibles | 17 | 17 | 17 | 18 | 18 |
Deposits & Other Assets | 8 | 4 | 1 | 2 | 2 |
Total Assets | 542 | 520 | 526 | 483 | 484 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 7 | 6 | 8 | 1 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 63 | 45 | 45 | 41 | 35 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 12 | 12 | 9 | 9 | 9 |
Total Current Liabilities | 84 | 64 | 64 | 53 | 47 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 12 | 12 | 12 | 12 | 12 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 2 | 2 | 2 | 2 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 107 | 88 | 87 | 78 | 73 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 935 | 928 | 917 | 908 | 901 |
Retained Earnings | -500 | -496 | -478 | -503 | -489 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 435 | 432 | 439 | 405 | 412 |
Total Liabilities & Shareholder's Equity | 542 | 520 | 526 | 483 | 484 |
Total Common Equity | 435 | 432 | 439 | 405 | 412 |
Shares Outstanding | 71.20 | 70.90 | 70.40 | 70.30 | 70.10 |
Book Value Per Share | 6.11 | 6.09 | 6.23 | 5.76 | 5.87 |